http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 15 Sep 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Sep+15/27065069.html si-local-file:///var/storage/secattach/20260915/27065069.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Sep+15/27065069.html Tue, 15 Sep 2026 16:16:00 -0400 PBLS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975919.html si-local-file:///var/storage/secattach/20260825/26975919.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975919.html Tue, 25 Aug 2026 18:14:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975919.html si-local-file:///var/storage/secattach/20260825/26975919.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975919.html Tue, 25 Aug 2026 18:14:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975909.html si-local-file:///var/storage/secattach/20260825/26975909.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975909.html Tue, 25 Aug 2026 18:05:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975909.html si-local-file:///var/storage/secattach/20260825/26975909.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22++Filed+by%3A+Tendler+Craig/26975909.html Tue, 25 Aug 2026 18:05:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22/26974765.html si-local-file:///var/storage/secattach/20260825/26974765.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22/26974765.html Tue, 25 Aug 2026 16:10:00 -0400 O.57149208 PBLS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22/26974765.html si-local-file:///var/storage/secattach/20260825/26974765.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Parabilis+Medicines%2C++++++For%3A+Aug+22/26974765.html Tue, 25 Aug 2026 16:10:00 -0400 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html <p>Parabilis Medicines (Nasdaq: PBLS) announced the appointment of Craig L. Tendler, M.D., to its board of directors, according to a company statement. Dr. Tendler previously served as Global Head of Late-Stage Clinical Development and Global Medical Affairs for Oncology at Johnson &amp; Johnson, where he spent two decades.</p> <p>Dr. Tendler brings more than 30 years of experience in oncology drug development and medical affairs. During his tenure at Johnson &amp; Johnson, he was involved in securing more than 30 oncology regulatory approvals, 13 FDA Breakthrough Therapy designations, and approvals for 15 New Molecular Entities. The approvals spanned treatments for prostate cancer, http://www.streetinsider.com/Board+Changes/Parabilis+Medicines+adds+former+J%26J+oncology+executive+to+board/26970685.html Tue, 25 Aug 2026 07:01:04 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html <p>CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson &amp; Johnson. He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibilities. <br/><br/>“We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html Tue, 25 Aug 2026 07:00:00 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html <p>CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson &amp; Johnson. He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibilities. <br/><br/>“We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html Tue, 25 Aug 2026 07:00:00 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html <p>CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson &amp; Johnson. He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibilities. <br/><br/>“We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html Tue, 25 Aug 2026 07:00:00 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html <p>CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson &amp; Johnson. He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibilities. <br/><br/>“We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html Tue, 25 Aug 2026 07:00:00 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html <p>CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson &amp; Johnson. He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibilities. <br/><br/>“We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html Tue, 25 Aug 2026 07:00:00 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html <p>CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler previously led both clinical development and medical affairs for oncology at Johnson &amp; Johnson. He has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his Board responsibilities. <br/><br/>“We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO http://www.streetinsider.com/Press+Releases/Parabilis+Medicines+Appoints+Accomplished+Drug+Development+Leader+Craig+L.+Tendler%2C+M.D.%2C+to+Board+of+Directors/26970649.html Tue, 25 Aug 2026 07:00:00 -0400 A.08988233 A.13945385 A.39305831 A.60001765 LEGN O.00170465 O.01845532 O.20738543 O.22949852 O.47731837 O.57149208 PBLS